|
|
| | ALLOCRYPTOPINE Basic information |
| Product Name: | ALLOCRYPTOPINE | | Synonyms: | ALPHA-ALLOCRYPTOPINE;ALLOCRYPTOPINE, ALPHA-;ALLOCRYPTOPINE;3,4-DIMETHOXY-6-METHYL-5,7,8,15-TETRAHYDRO-6H-BENZO[C][1,3]DIOXOLO[4',5':4,5]BENZO[1,2-G]AZECIN-14-ONE;.beta.-Allocryptopine;.gamma.-Homochelidonine;Benzo[E][1,3]dioxolo[4,5-K][3]benzazecin-14(6H)-one, 5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl-;Fagarine i | | CAS: | 24240-04-8 | | MF: | C21H23NO5 | | MW: | 369.41 | | EINECS: | | | Product Categories: | | | Mol File: | 24240-04-8.mol |  |
| | ALLOCRYPTOPINE Chemical Properties |
| Melting point | 169-170 °C | | Boiling point | 552.7±50.0 °C(Predicted) | | density | 1.216±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | Powder | | pka | 7.86±0.20(Predicted) | | biological source | plant | | Water Solubility | water: slightly soluble | | Major Application | metabolomics
vitamins, nutraceuticals, and natural products | | InChI | 1S/C21H23NO5/c1-22-7-6-14-9-19-20(27-12-26-19)10-15(14)17(23)8-13-4-5-18(24-2)21(25-3)16(13)11-22/h4-5,9-10H,6-8,11-12H2,1-3H3 | | InChIKey | HYBRYAPKQCZIAE-UHFFFAOYSA-N | | SMILES | N1(CCc2c(cc4c(c2)OCO4)C(=O)Cc3c(c(c(cc3)OC)OC)C1)C |
| Storage Class | 11 - Combustible Solids |
| | ALLOCRYPTOPINE Usage And Synthesis |
| Chemical Properties | White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from Macleaya cordata and Corydalis yanhusuo. | | Uses | It is a natural product derived from plant source th at finds application in compound screening libraries, metabolomics, phytochemical, and pharmaceutical research. | | Definition | ChEBI: Allocryptopine is a dibenzazecine alkaloid, an organic heterotetracyclic compound, a tertiary amino compound, a cyclic ketone, a cyclic acetal and an aromatic ether. | | Biological Activity | Allocryptopine has been reported to possess strong antibacterial, anti-inflammatoty, antiparasitic, antineoplastic and anti-addictive activities. Allocryptopine inhibits human acetylcholinesterase and butyrylcholinesterase. It blocks hERG current in HEK293 cells. Allocryptopine strongly enhanced the I(peak) of the T353I channel by enhancing the plasma membrane (PM) expression of Nav1.5 and rescued defective trafficking after co-incubation with HEK293 cells th at carry mutation channel 24 h. | | target | cAMP | P450 (e.g. CYP17) |
| | ALLOCRYPTOPINE Preparation Products And Raw materials |
|